uniQure N.V. (QURE)
- Previous Close
4.6800 - Open
4.6900 - Bid 4.9000 x 100
- Ask 4.9600 x 300
- Day's Range
4.6600 - 5.0500 - 52 Week Range
4.2500 - 20.8400 - Volume
525,857 - Avg. Volume
770,287 - Market Cap (intraday)
240.32M - Beta (5Y Monthly) 0.98
- PE Ratio (TTM)
-- - EPS (TTM)
-6.1700 - Earnings Date Jul 30, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
19.08
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
www.uniqure.comRecent News: QURE
Performance Overview: QURE
Trailing total returns as of 5/31/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: QURE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: QURE
Valuation Measures
Market Cap
239.35M
Enterprise Value
-179.23M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
12.48
Price/Book (mrq)
1.64
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-22.11%
Return on Equity (ttm)
-106.11%
Revenue (ttm)
19M
Net Income Avi to Common (ttm)
-296.87M
Diluted EPS (ttm)
-6.1700
Balance Sheet and Cash Flow
Total Cash (mrq)
555.68M
Total Debt/Equity (mrq)
369.67%
Levered Free Cash Flow (ttm)
-65.85M